<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798861</url>
  </required_header>
  <id_info>
    <org_study_id>204560</org_study_id>
    <nct_id>NCT02798861</nct_id>
  </id_info>
  <brief_title>Controlled Attenuation Parameter (CAP) in Liver Allografts</brief_title>
  <official_title>Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres Duarte-Rojo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis&#xD;
      using liver biopsies as reference. Secondarily, investigators will correlate transient&#xD;
      elastography (TE) and CAP results, analyze possible associations between CAP/TE and&#xD;
      post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The&#xD;
      study aims to include as many donors as needed to achieve at least 120 transplanted liver&#xD;
      allografts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a coordinated study utilizing 3 recruitment centers (University of Arkansas for&#xD;
      Medical Sciences [UAMS], Stanford University, and Mayo Clinic) 2 liver pathology reading&#xD;
      centers (University of Michigan and Mayo Clinic), and 1 coordinating center (University of&#xD;
      Arkansas). The cohort study with a cross-sectional component for the primary aim has been&#xD;
      completed (through independent Institutional Review Board [IRB] agreements) at UAMS, Stanford&#xD;
      University, and the Mayo Clinic. The samples collected at the three recruitment centers will&#xD;
      be sent to the biopsy center at the University of Michigan and Mayo Clinic for evaluation.&#xD;
      The Liver Transplant Program at each of the 3 recruiting centers will identify study subjects&#xD;
      during the process of liver allocation to their listed recipients. Criteria for recruitment&#xD;
      are as follows:&#xD;
&#xD;
      Inclusion criteria - Liver Recipient&#xD;
&#xD;
        -  Men and women, Age 18-years old to 80-years old inclusive Inclusion criteria - Liver&#xD;
           Donor&#xD;
&#xD;
        -  Valid TE with Fibroscan 530, defined as:&#xD;
&#xD;
             -  At least 10 valid measurements&#xD;
&#xD;
             -  Interquartile Range (IQR)/Median stiffness value &lt;30% (only in cases with &gt;7.1 kPa)&#xD;
                Exclusion criteria - Liver Recipient&#xD;
&#xD;
        -  Patient did not undergo liver transplantation Exclusion criteria - Liver Donor&#xD;
&#xD;
        -  Donation after circulatory death (DCD)&#xD;
&#xD;
        -  No liver biopsy obtained during organ procurement process&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2016</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Controlled Attenuation Parameter (CAP) - Accuracy</measure>
    <time_frame>Baseline (pre-procurement) to 6 months post liver transplant</time_frame>
    <description>CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LSM</measure>
    <time_frame>Pretransplant to 6 months posttransplant</time_frame>
    <description>Liver stiffness measurement</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Liver Transplant</condition>
  <condition>Liver Steatosis</condition>
  <condition>Liver Disease</condition>
  <condition>Primary Non-function</condition>
  <condition>Early Allograft Dysfunction</condition>
  <arm_group>
    <arm_group_label>CAP assessment</arm_group_label>
    <description>Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fibroscan 402/530</intervention_name>
    <description>Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.</description>
    <arm_group_label>CAP assessment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Allograft procured and transplanted into recipients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria - Liver Recipient&#xD;
&#xD;
          -  Men and women, Age 18-years old to 80-years old inclusive&#xD;
&#xD;
        Inclusion criteria - Liver Donor&#xD;
&#xD;
          -  Valid TE with Fibroscan 402/530, defined as:&#xD;
&#xD;
               -  At least 10 valid measurements&#xD;
&#xD;
               -  IQR/Median stiffness value &lt;30% (only in cases with &gt;7.1 kPa)&#xD;
&#xD;
        Exclusion criteria - Liver Recipient&#xD;
&#xD;
          -  Patient did not undergo liver transplantation&#xD;
&#xD;
        Exclusion criteria - Liver Donor&#xD;
&#xD;
          -  Donation after circulatory death (DCD)&#xD;
&#xD;
          -  No liver biopsy obtained during organ procurement process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Duarte-Rojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <results_first_submitted>June 2, 2020</results_first_submitted>
  <results_first_submitted_qc>July 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Andres Duarte-Rojo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02798861/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allografts</title>
          <description>Livers assessed before procurement and after implantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAP Assessment</title>
          <description>Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes&#xD;
Fibroscan 402/530: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="21" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AST</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" lower_limit="43" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAP</title>
          <units>dB/m</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235" lower_limit="188" upper_limit="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LSM</title>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.25" lower_limit="5.7" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Controlled Attenuation Parameter (CAP) - Accuracy</title>
        <description>CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference</description>
        <time_frame>Baseline (pre-procurement) to 6 months post liver transplant</time_frame>
        <population>Here are considered the allografts that were transplanted and whose recipients consented to participate in study</population>
        <group_list>
          <group group_id="O1">
            <title>CAP Assessment</title>
            <description>Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes&#xD;
Fibroscan 402/530: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 6 months post-transplant in the liver recipient.</description>
          </group>
        </group_list>
        <measure>
          <title>Controlled Attenuation Parameter (CAP) - Accuracy</title>
          <description>CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference</description>
          <population>Here are considered the allografts that were transplanted and whose recipients consented to participate in study</population>
          <units>dB/m</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" lower_limit="176" upper_limit="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LSM</title>
        <description>Liver stiffness measurement</description>
        <time_frame>Pretransplant to 6 months posttransplant</time_frame>
        <population>Here are considered the allografts that were transplanted and whose recipients consented to participate in study</population>
        <group_list>
          <group group_id="O1">
            <title>CAP Assessment</title>
            <description>Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes&#xD;
Fibroscan 402/530: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 6 months post-transplant in the liver recipient.</description>
          </group>
        </group_list>
        <measure>
          <title>LSM</title>
          <description>Liver stiffness measurement</description>
          <population>Here are considered the allografts that were transplanted and whose recipients consented to participate in study</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4.7" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No adverse event data were collected because the study was observational.</time_frame>
      <desc>No adverse event data were collected because the study was observational.</desc>
      <group_list>
        <group group_id="E1">
          <title>CAP Assessment</title>
          <description>Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes&#xD;
Fibroscan 402/530: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 6 months post-transplant in the liver recipient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andres Duarte-Rojo</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-647-7922</phone>
      <email>duarterojoa@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

